Company: BUDZ
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001096906-25-000350
Chunk: 9

Company: WEED, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1
Chunk 9
---
antages

Sangre’s research
and development team works with next generation sequencing (NGS) and emerging third generation instruments and has developed the most
advanced proprietary bioinformatics data systems available. Sangre uses a unique two sequencing approach. One system provides DNA reads
of up to 300,000 base pair reads and an NGS system which provides highly accurate short reads. This allows the genomic data to be assembled
in a scaffold construct; the long reads forming the scaffold and the short reads providing highly accurate verification and quality assurance
of the genomic data. This approach, together with the bioinformatics program, facilitates a highly accurate construct of the Cannabis
genome which can be annotated and facilitate gene discovery and gene location. Sangre combination of personnel, skill-sets, and data analytics
capabilities will allow us to accomplish our goals in months, rather than years.

Using annotated genomic
data and newly generated phenotypic data, we plan to identify and isolate regions of the genome which are related to growth, synthesis
of desired molecules, and environmental compatibility. This complex data set will be utilized in a breeding program to generate and establish
new hybrid cultivars which exemplify the traits that are desired by the medical community. This breeding program will produce new seed
stocks, clones, cultivars, and intellectual property which will generate value for the business organization. Eventual expansion to Israel
will allow us to include human clinical trials thru product development for its domestic and international export markets. WEED looks
to conduct these trials to meet the level of FDA required testing in hopes to speed up acceptance in USA once legally allowable.

Sangre plans to develop
a translational breeding program to establish a new collection of Cannabis cultivars for the USA national market. In Israel we plan to
establish a unique 2nd new collection of Cannabis Cultivars exclusive to WEED for the EU, Australian and Asian marketplace. Using genetic
screening technology and micro-propagation, cultivars can be up-selected for specific traits and grown to address the needs of consumers
in the medicinal and drug discovery markets. The combination of next generation genomics, selective hybridization, and In Vitro cloning
provide us with the tools to enhance new cultivars of patentable Cannabis.

Marketing

We have not developed a
marketing plan and do not intend to until we are in the latter stages of the Cannabis Genomic Study and believe we have strains that are
marketable for the treatment of disease. At that time we plan to develop a marketing plan for our newly